Filtered By:
Source: Vaccine

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 21 results found since Jan 2013.

Influenza and pneumococcal vaccination and risk of stroke or transient ischaemic attack-Matched case control study.
CONCLUSIONS: Influenza vaccination was associated with a 24% reduction in risk of stroke but not TIA. Pneumococcal vaccination was not associated with reduced risk of stroke or TIA. This has important implications for potential benefits of influenza vaccine. PMID: 24486370 [PubMed - as supplied by publisher]
Source: Vaccine - January 28, 2014 Category: Allergy & Immunology Authors: Siriwardena AN, Asghar Z, Coupland CA Tags: Vaccine Source Type: research

Influenza vaccination and risk of stroke: Self-controlled case-series study.
CONCLUSIONS: Influenza vaccination is associated with a reduction in incidence of stroke. This study supports previous studies which have shown a beneficial association of influenza vaccination for stroke prevention. PMID: 26296496 [PubMed - as supplied by publisher]
Source: Vaccine - August 18, 2015 Category: Allergy & Immunology Authors: Asghar Z, Coupland C, Siriwardena N Tags: Vaccine Source Type: research

Association of pneumococcal vaccination with cardiovascular diseases in older adults: The vaccine effectiveness, networking, and universal safety (VENUS) study
This study aimed to investigate the protective effect of PPSV23 on cardiovascular events in adults aged ≥ 65 years. This population-based nested case-control study was conducted using the claims data and vaccine records between April 2015 and March 2020 from the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study. PPSV23 vaccination was identified using vaccination records in each municipality. The primary outcome was acute myocardial infarction (AMI) or stroke. The adjusted odds ratios (aORs) with 95% confidence intervals (CIs) for PPSV23 vaccination were calculated using conditional logistic regressio...
Source: Vaccine - March 4, 2023 Category: Allergy & Immunology Authors: Nobuhiro Narii Tetsuhisa Kitamura Sho Komukai Ling Zha Masayo Komatsu Fumiko Murata Megumi Maeda Kosuke Kiyohara Tomotaka Sobue Haruhisa Fukuda Source Type: research

Assessment of pre-specified adverse events following varicella vaccine: A population-based self-controlled risk interval study.
CONCLUSIONS: We detected a small risk of incidental pneumonia associated with varicella vaccine in the 6th week after immunization. There was no increase in the risk of other pre-specified adverse events. PMID: 32046891 [PubMed - as supplied by publisher]
Source: Vaccine - February 7, 2020 Category: Allergy & Immunology Authors: Liu CH, Yeh YC, Huang WT, Chie WC, Chan KA Tags: Vaccine Source Type: research

Clinical features of adults with seven-valent-conjugated-vaccine-serotype pneumococcal pneumonia.
CONCLUSION: A significant proportion of adults continue to develop PCV7-serotype CAP in the era of childhood pneumococcal conjugate vaccination. These adults are more likely to have stroke and dementia as underlying co-morbid illnesses, and have a higher 30-day mortality. A combination of pneumococcal transmission factors, host factors and pneumococcal serotype specific characteristics are likely to explain these findings. PMID: 24508039 [PubMed - as supplied by publisher]
Source: Vaccine - February 6, 2014 Category: Allergy & Immunology Authors: Rodrigo C, Bewick T, Sheppard C, Greenwood S, Trotter C, Slack M, George R, Lim WS Tags: Vaccine Source Type: research

Vaccine safety in HIV-infected adults within the Vaccine Safety Datalink Project.
CONCLUSIONS: Routinely administered vaccines are generally safe for HIV-infected adults. PMID: 31064675 [PubMed - as supplied by publisher]
Source: Vaccine - May 3, 2019 Category: Allergy & Immunology Authors: Hechter RC, Qian L, Tartof SY, Sy LS, Klein NP, Weintraub E, Mercado C, Naleway A, McLean HQ, Jacobsen SJ Tags: Vaccine Source Type: research

Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic
CONCLUSION: Rates of some clinical outcomes during the pandemic changed and should not be used as historical background rates in vaccine safety studies. Inclusion of telehealth visits should be considered for vaccine studies involving Bell's palsy, ITP, and narcolepsy/cataplexy.PMID:35465977 | DOI:10.1016/j.vaccine.2022.04.037
Source: Vaccine - April 25, 2022 Category: Allergy & Immunology Authors: Stanley Xu Vennis Hong Lina S Sy Sungching C Glenn Denison S Ryan Kerresa L Morrissette Jennifer C Nelson Simon J Hambidge Bradley Crane Ousseny Zerbo Malini B DeSilva Jason M Glanz James G Donahue Elizabeth Liles Jonathan Duffy Lei Qian Source Type: research

Effectiveness of the influenza vaccine at reducing adverse events in patients with heart failure: A systematic review and meta-analysis
CONCLUSIONS: Influenza vaccination appears to reduce adverse cardiovascular events, although the certainty of the evidence is low or very low. Rigorous randomized controlled trial evidence is needed to further examine the protective effect of the influenza vaccine in heart failure patients.PMID:35562195 | DOI:10.1016/j.vaccine.2022.04.039
Source: Vaccine - May 13, 2022 Category: Allergy & Immunology Authors: Christopher Gupta Anjali Sachdeva Jigish Khamar Cecilia Bu Jessica Bartoszko Mark Loeb Source Type: research

Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study
CONCLUSION: This study shows acceptable safety profiles of COVID-19 vaccines among recipients of BNT162b2, CoronaVac, and ChAdOx1 vaccines. This information can be used together with effectiveness data for risk-benefit analysis of the vaccination program. Further surveillance with more data is required to assess AESIs following COVID-19 vaccination in short- and long-term.PMID:35667917 | DOI:10.1016/j.vaccine.2022.05.075
Source: Vaccine - June 6, 2022 Category: Allergy & Immunology Authors: Norazida Ab Rahman Ming Tsuey Lim Fei Yee Lee Sing Chet Lee Azuana Ramli Siti Nurhafizah Saharudin Teck Long King Emelyne Bani Anak Jam Nor Aliya Ayub Raj Kumar Sevalingam Rashidah Bahari Nor Nadziroh Ibrahim Fatihah Mahmud Sheamini Sivasampu Kalaiarasu M Source Type: research

Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine.
CONCLUSIONS: In this safety surveillance study of more than 200,000 DTaP-IPV vaccine recipients, there was no evidence of increased risk for any of the pre-specified adverse events monitored. Continued surveillance of DTaP-IPV vaccine safety may be warranted to monitor for rare adverse events, such as Guillain-Barré syndrome. PMID: 24699471 [PubMed - as supplied by publisher]
Source: Vaccine - March 31, 2014 Category: Allergy & Immunology Authors: Daley MF, Yih WK, Glanz JM, Hambidge SJ, Narwaney KJ, Yin R, Li L, Nelson JC, Nordin JD, Klein NP, Jacobsen SJ, Weintraub E Tags: Vaccine Source Type: research

Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials.
CONCLUSIONS: HZ/su reduces the risk of HZ-associated complications in older adults (NCT01165177; NCT01165229). PMID: 29463421 [PubMed - as supplied by publisher]
Source: Vaccine - February 17, 2018 Category: Allergy & Immunology Authors: Kovac M, Lal H, Cunningham AL, Levin MJ, Johnson RW, Campora L, Volpi A, Heineman TC, ZOE-50/70 Study Group Tags: Vaccine Source Type: research

High-dose influenza vaccines for the prevention of hospitalization due to cardiovascular events in older adults in the nursing home: Post-hoc analysis of a cluster-randomized trial
Vaccine. 2022 Oct 13:S0264-410X(22)01215-4. doi: 10.1016/j.vaccine.2022.09.085. Online ahead of print.ABSTRACTOlder adults are at high risk of major acute cardiovascular events (MACE) linked to influenza illness andpreventable by influenza vaccination. It is unknown whether high-dose vaccine might incrementally reduce the risk of MACE.We conducted a post-hoc analysis of data collected from a pragmatic cluster randomized study of 823 nursing homes (NH) randomized to standard-dose (SD) or high-dose (HD) influenza vaccine in the 2013-14 season. Adults age 65 year or older who are Medicare-enrolled long-stay residents were inc...
Source: Vaccine - October 16, 2022 Category: Allergy & Immunology Authors: Elie A Saade Yasin Abul Kevin McConeghy H Edward Davidson Lisa Han Nina Joyce David H Canaday Leon Hsueh Elliott Bosco Stefan Gravenstein Source Type: research